Investors shouldn’t be apprehensive about the recent facility shutdowns from the biggest cannabis name in Canada, one portfolio manager said.

“It’s a big announcement (but) I don’t think it’s a surprise,” Charles Taerk, CEO of Faircourt Asset Management, a sub-advisor to Ninepoint Partners’ cannabis-focused fund, said in reaction to the shutdown of operations at two key facilities in British Columbia (BC) owned by Canopy Growth (NYSE:CGC,TSX:WEED).

After trading hours on Wednesday (March 4), Canopy confirmed it was closing its facilities in Aldergrove and Delta, BC, eliminating approximately 500 positions.

In an interview with the Investing News Network (INN), Taerk said Canopy’s move to end its operations at these facilities is ultimately a positive one.

He noted that rightsizing plans for Canopy had been previously discussed with the February release of its Q3 2020 results.

In an earnings call with investors and analysts at the time, CEO David Klein said the firm wanted to streamline its business in the coming months.

“Mindful of future market growth, we’re prepared to take initial steps to rightsize our business over the next 90 days,” Klein said during the call.

Aside from cost cutting measures, Taerk said that Canopy’s BC operations were allegedly rife with issues of quality concerns and inconsistency since the company took over the two facilities in 2018.

Canopy, for its part, saw a drop in the open market in Toronto. On Thursday (March 5), shares fell over 5 percent nearing the end of the trading session with prices sitting at C$22.48 as of 2:45 p.m. EST.

The Ontario-based producer also announced it is scraping a plan to build a third greenhouse in Niagara-on-the-Lake and expects to record about C$700 million to C$800 million in pre-tax charges for the quarter ending March 31.

“Today’s decision moves us in this direction, and although the decision to close these facilities was not taken lightly, we know this is a necessary step to ensure that we maintain our leadership position for the long-term,” Klein said in a press release.

Canopy told investors that these recent moves, which were done in order to slim down operations, will aid to “align supply and demand while improving production efficiencies over time.”

The combined size of the two BC facilities comes up to about 3 million square feet of licensed cultivation space, Canopy Growth said, originally retrofitted to keep up with projected demand. In its November MD&A filing, Canopy said they had approximately 5.4 million in licensed cultivation capacity, meaning that the closures have more than halved its production capacity, dropping it by 55.6 percent.

Struggles facing the Canadian cannabis sector, including regulatory hurdles and a small retail space, have somewhat suppressed the industry’s growth.

“Nearly 17 months after the creation of the legal adult-use market, the Canadian recreational market has developed slower than anticipated, creating working capital and profitability challenges across the industry,” Canopy Growth noted.

Canopy plans to focus instead on its outdoor production site for more cost-effective cultivation.

Taerk said these moves by Canopy are indicative of a shift to productivity over size for the industry.

The fund manager mentioned that other larger licensed producers in Canada, such as Aurora Cannabis (NYSE:ACB,TSX:ACB) and HEXO (NYSE:HEXO,TSX:HEXO), were on a quick path to build cultivation.

Now, however, the winners of the space will be the ones that are keen to carefully use capital.

“To be the biggest isn’t necessarily going to make you the most efficient,” he said, adding that some cannabis firms have gone on to become cashflow positive by lowering operation and cultivation costs. “They’re showing shareholders that they are better stewards of capital.”

The pressure felt across the sector is something Taerk said is largely a result of a tight capital market.

“I think that there are many companies that are finding it difficult to operate in this capital constrained environment,” he said. Despite the difficulties, Taerk explained that investors are willing to contribute to companies that can prove they’re generating revenue.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less

Company establishes bit mining infrastructure for long term revenue generation

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to announce that it has signed a $2.5 million (USD) definitive agreement as of January 14th, 2021, to acquire bit mining infrastructure based in the USA for long term revenue generation

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it is commencing a best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company.

Keep reading... Show less